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Abstract 
IMPORTANCE It is unclear whether physiotherapy and occupational therapy are clinically 
and cost-effective in Parkinson's disease. 
OBJECTIVE To perform a large pragmatic randomised trial to evaluate the clinical and cost-
effectiveness of individualised physiotherapy and occupational therapy in Parkinson's 
disease. 
DESIGN, SETTING, AND PATIENTS PD REHAB was a multicenter, open label, parallel 
group, controlled efficacy trial. 762 patients with mild-moderate Parkinson’s disease were 
recruited from 38 sites across the United Kingdom. Recruitment took place between October 
2009 and June 2012. 
INTERVENTIONS Participants with limitations in activities of daily living (ADL) were 
randomised to physiotherapy and occupational therapy or no therapy.  
MAIN OUTCOMES AND MEASURES The primary outcome was the Nottingham Extended 
Activities of Daily Living (NEADL) scale at 3 months post-randomisation. Secondary 
outcomes were: health-related quality of life (QoL; Parkinson's Disease Questionnaire-39, 
PDQ-39; EuroQol-EQ-5D); adverse events; carer QoL. Outcomes were assessed before, 3, 
9, and 15 months post-randomisation. 
RESULTS At 3 months, there was no difference between groups in NEADL total score 
(difference 0·5 points, 95% CI -0·7 to 1·7; p=0·4) or PDQ-39 summary index (0·007 points, 
95% CI -1·5 to 1·5; p=1·0). EuroQol-EQ-5D quotient was of borderline significance in favour 
of therapy (-0·03, 95% CI -0·07 to -0·002; p=0·04). Median therapist contact time was four 
visits of 58 minutes over 8 weeks. Repeated measures analysis showed no difference in 
NEADL total score, but PDQ-39 summary index (diverging 1.6 points per annum, 95% CI 
0.47 to 2.62; p=0.005) and EuroQol-EQ-5D (0.02, 95% CI 0.00007 to 0.03; p=0.04) showed 
small differences in favour of therapy. There was no difference in adverse events. 
CONCLUSIONS AND RELEVANCE Physiotherapy and occupational therapy did not 
produce immediate or medium term clinically meaningful improvements in ADL or QoL in 
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mild-moderate Parkinson’s disease. This evidence does not support the use of low dose, 
patient-centered, goal-directed physiotherapy and occupational therapy in patients in the 
early stages of Parkinson's disease. Future research should explore the development and 
testing of more structured and intensive physical and occupational therapy programmes in 
patients with all stages of Parkinson's disease. 
TRIAL REGISTRATION ISRCT17452402. 
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Introduction 
Parkinson's disease causes problems with activities of daily living (ADL) that are only 
partially treated by medication and occasionally surgery. Despite treatment, patients go on to 
develop intractable motor problems including falls, with mental health problems and other 
non-motor symptoms. Physiotherapy and occupational therapy are traditionally used later in 
the disease.1 However, service provision varies widely, with some centers involving 
physiotherapists and occupational therapists from diagnosis, while other areas have no 
specialist services.  
Cochrane reviews of physiotherapy for Parkinson’s disease found small but significant 
effects on motor function, but not quality of life.2,3 A Cochrane review of occupational therapy 
found insufficient evidence of effectiveness.4 Previous trials with both therapies were small 
with short-term follow-up.2-4 Despite this lack of evidence, the UK National Institute for Health 
and Care Effectiveness guidelines, although recognising these shortcomings and 
recommending further trials, stated that all patients should have access to both therapies.1  
The PD REHAB trial was designed to evaluate the clinical and cost-effectiveness of 
individualised physiotherapy and occupational therapy in patients with Parkinson’s disease. 
The current trial design was informed by our pilot study of occupational therapy in 
Parkinson’s disease (PD OT).5 
Methods 
PD REHAB was a large-scale pragmatic multicenter randomised controlled trial to evaluate 
the effects of individualised physiotherapy and occupational therapy on ADL and quality of 
life (QOL) in patients with Parkinson’s disease. The trial protocol (last accessed 5th 
November 2015) is available at: http://www.birmingham.ac.uk/pdrehab-docs. 
Study participants 
Recruitment took place between October 2009 and June 2012. Patients from 38 neurology 
or geriatric medicine outpatient centers across the UK were invited to take part. Eligibility 
criteria were: idiopathic Parkinson’s disease defined by UK Parkinson’s Disease Society 
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Brain Bank Criteria;6 self or carer reported limitations in ADL; and the investigator was 
uncertain that they would require physiotherapy and/or occupational therapy during the 15 
months of the trial, i.e. equipoise about the need for therapy existed Exclusion criteria were: 
dementia as locally defined; receipt of physiotherapy or occupational therapy for Parkinson’s 
disease in the last 12 months. All patients gave written informed consent before 
randomisation. Ethical approval was granted by the West Midlands Research Ethics 
Committee (08/H1211/168) and local approval was obtained at each participating center. 
Randomisation and Therapy Allocation 
Patients were randomised (1:1) between combined physiotherapy and occupational therapy 
(therapies group) or no therapy (control group) using an on-line randomisation service at the 
University of Birmingham Clinical Trials Unit. Randomisation used a computer-based 
algorithm with minimisation by baseline Nottingham Extended Activities of Daily Living 
(NEADL) total score (severe 0 to 21; moderate 22 to 43; mild limitations in ADL 44 to 66), 
Hoehn and Yahr stage (H&Y)7 (≤2; 2.5; 3;≥4) and age (<60; 60 to 69; 70 to 79; ≥80 years). 
Intervention 
Physiotherapy and occupational therapy were delivered in the community and/or outpatients 
by qualified therapists working within the National Health Service (NHS) per local practice. 
Before the trial, a framework for therapy content was developed and agreed by expert 
therapist groups based on previous work on standards of NHS physiotherapy and 
occupational therapy and European guidelines.8-11 This framework was based on usual NHS 
practice and not an innovative intervention. Following initial assessments by both therapists, 
therapy was tailored to individual patient's requirements using a patient-centered joint goal 
setting approach. Interactions between therapists and patients were described and 
quantified using pre-defined recording forms and included administration time (e.g. ordering 
equipment). Controls consented to have therapies deferred until the end of the 15 month 
trial, unless pressing reasons for therapy developed. Since therapies may have been 
arranged outside the trial, controls were asked whether they had received any therapy at 
each assessment point. 
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Primary outcome measure 
Total NEADL score at 3 months post-randomisation was the primary outcome measure.12 
NEADL measures instrumental ADL which are specifically addressed by physiotherapy and 
occupational therapy and includes more complex ADL issues such as making a meal, 
cleaning and travelling on public transport. The NEADL scale was developed for stroke, but 
is used widely as a generic outcome measure in rehabilitation trials of older people. It is 
sensitive to change in occupational therapy trials,13 and was successfully used in our pilot 
study of occupational therapy for Parkinson’s disease, with good correlation with the Unified 
Parkinson's Disease Rating Scale and the Parkinson’s Disease Questionnaire (PDQ-39) 
ADL domains.5  
Secondary outcome measures were patient-rated QOL using the 39-item PDQ-39,14 
comprised of eight domains and the most widely used disease-specific QOL rating scale for 
Parkinson’s disease, and EuroQol-5D (EQ-5D; 3 level version), a generic QOL scale; 
adverse events; and carer well-being using Short Form-12 (SF-12; version 2). Following a 
risk assessment, only therapy-related adverse events and serious adverse events were 
recorded. These were defined as falls or equipment failure leading to injury requiring a 
hospital, general practitioner (GP), ambulance visit, or death. A health economics analysis 
was conducted alongside PD REHAB and will be reported separately. Outcomes were 
collected in person at baseline before randomisation, then by post at 3, 9, and 15 months 
after randomisation. Anti-parkinsonian medication dosage was converted into levodopa dose 
equivalents using a standard formula.15  
Statistical analysis 
A minimally clinically important change (MCIC) in NEADL score in stroke patients is 1 to 2 
points.16 However, such a small change may be of little benefit to patients; a clinically 
meaningful change in NEADL for patients is likely to be around double this at 2·5 points. A 2 
point change in NEADL score represents becoming independent in one item (e.g. stair 
climbing, crossing roads) or improvement in two items (e.g. being dependent on another 
person with help to being fully independent). To detect a 2·5 point difference in NEADL at 3 
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months (using the observed standard deviation (SD) from the PD OT pilot trial5 of 10·1 
points; p=0·05 two tailed; 90% power) required 340 patients in each group: increased to 750 
participants (375 per group) to allow for around 10% non-compliance and drop-out. 
The primary analysis was change in NEADL total score in the therapies group between 
baseline and the 3 month assessment compared with that in the no therapy group. An 
independent two-sample t-test was used to compare changes between baseline and 3 
months in the NEADL score between the two groups. Results are presented as mean 
difference between groups with 95% confidence interval (CI). This analysis was repeated for 
individual NEADL domains and secondary outcome measures. The medium term effect or 
whether any benefit of treatment persisted beyond the initial intervention period was 
evaluated at 9 and 15 months post-randomisation, using both t-tests at each time point and 
a mixed model repeated measures analysis across all time points for all outcomes. 
Analyses were performed on an intention-to-treat basis. Missing data in PDQ-39 domain 
scores were imputed using an expectation maximisation algorithm.17 18 There is no 
established imputation method for the NEADL scale, therefore primary analyses used 
available data only, with no imputation for missing values. However, sensitivity analyses 
using a best (score 3), worst (score 0), middle (score 1.5), and average (at participant level) 
case score for missing items on the NEADL were explored. Three a priori subgroup analyses 
employed a test of interaction to explore the effect of the therapies at different levels of ADL, 
disease stage, and age at 3 months. All subgroup analyses were interpreted cautiously. 
Analyses were performed using SAS version 9·2 (Cary, NC, USA). Interim analyses of un-
blinded efficacy and safety data were reviewed annually by an independent Data Monitoring 
Committee which reported to an independent Trial Steering Committee. 
Results 
Study Population 
762 people with Parkinson’s disease were randomised to either combined physiotherapy 
and occupational therapy or no therapy (381 per group; CONSORT diagram, Figure 1). 
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Baseline characteristics were similar between groups (Table 1). Mean age was 70 years, 
65% were male and median disease duration was 3·1 years (mean 4·6 years). Most patients 
had mild to moderate disease, with 67% in H&Y ≤2 and median NEADL total score 54 (mean 
51). 
At 3 months, 92% of patients in each arm had completed the NEADL (Figure 1). By 15 
months, 311 (82% of 381 patients randomised) in the therapies arm had completed the 
NEADL compared with 322 (85% of 381 patients randomised) in the control arm. 
25 patients (6%) allocated to the therapies arm did not receive therapy by 3 months post-
randomisation (12 started physiotherapy and/or occupational therapy after 3 months and 13 
never received any therapy; Figure 1). Nine patients (2%) allocated to no therapy received 
therapy for Parkinson’s disease-related problems within 3 months, mainly worsening 
Parkinson’s disease symptoms including falls and imbalance (Figure 1).  
Therapy content 
In the therapies group, the median total number of therapy sessions was four (range 1-21), 
with a mean time per session of 58 minutes. Mean duration of therapy was 8 weeks. Mean 
total dose of both therapies was 263 minutes (range 38-1198). Most physiotherapy was 
performed in outpatients (53%) rather than the community (39%), or other (8%), whereas 
occupational therapy was more commonly performed in the community (69%) rather than 
outpatients (29%), or other (2%). 
Physiotherapy logs showed the most frequent interventions were for gait (96% of patients), 
posture (93%), balance (90%), physical conditioning (81%), and transfers (78%). 
Occupational therapy logs showed the most frequent interventions were for transfers (45%), 
dressing and grooming (36%), sleep and fatigue (31%), indoor mobility (28%), household 
tasks (28%), and other environmental issues (27%). 
Validation of therapy logs was undertaken by comparing logs with full-text therapy notes for 
38 patients chosen at random from 10 geographically diverse centers. Interventions were 
grouped into: assessment, equipment/adaptation prescription, exercise recommendations, 
referral to other specialists, and ‘other advice’. Physiotherapists prescribed a range of 
9 
 
exercise programmes tailored to their assessment of patient mobility and activity levels. Only 
three physiotherapists provided specific Parkinson’s disease exercise advice accompanied 
by a booklet, and there was no evidence of a formal exercise progression protocol for any 
patient. Occupational therapy assessed the full range of ADL, but predominant interventions 
were equipment provision, onward referral, and ‘other advice’ (e.g. management of sleep 
disorders, applying for benefits). There was little task-related practice.  
Outcome measures 
Mean NEADL total score deteriorated from baseline to 3 months by 1·5 points in the 
therapies group compared with 1·0 point in the no therapy group (difference 0·5 points, 95% 
CI -0·7-+1·7, p=0·4; Table 2). No difference was seen in any of the individual categories of 
the NEADL scale (Table 2). Repeated measures analysis of the NEADL across all time 
points showed no difference between the treatment arms (Figure 2; eTable 1). 
Mean PDQ-39 summary index deteriorated by 2·4 points in both groups from baseline to 3 
months (difference 0·007 points, 95% CI -1·5-+1·5, p=1·0; Table 2). No difference was seen 
in any of the eight domains of the PDQ-39 (Table 2). The slight improvement of 0·002 points 
in the EuroQol EQ-5D quotient in the therapies group between baseline and 3 months 
compared with a 0·03 point deterioration in the no therapy group was of borderline 
significance (difference -0·03, 95% CI -0·07--0·002, p=0·04; Table 2). There was no 
difference in the EuroQol EQ-5D visual analogue score (difference -0·2, 95% CI -2·6-+2·2, 
p=0·9; Table 2). 
Repeated measures analysis over 15 months found significant divergence in PDQ-39 
summary index (curves diverging at 1.55 points per annum, 95% CI 0.47-2.62; p=0.005; 
Figure 2) and the ADL, emotional well-being, and social support domains changed in favour 
of therapy (eTable 2), but there was no difference in the mobility domain. There was also a 
borderline significant difference in the EuroQol EQ-5D quotient in favour of the therapies arm 
over time (0.02, 95% CI 0.00007-0.03; p=0.04; Figure 2). 
Sensitivity analysis with imputation of missing NEADL values did not change the results. 
Repeating the PDQ-39 analysis without imputation of missing values using the expectation 
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maximisation algorithm also did not affect the results. We analysed the primary outcome of 
mean change between baseline and 3 months for NEADL total score data using analysis of 
covariance adjusting for baseline NEADL score and the other minimisation variables, but this 
made no difference to the result. 
Planned subgroup analyses for NEADL total score found no evidence of difference in 
therapy effect at 3 months according to baseline total NEADL score, age, or disease severity 
(eFigure 1). 
Four hundred and seventy three (62%) patients had a carer and 406 (86%) carers agreed to 
take part in the trial (mean age 67 years; 76% female). The relationship between patient and 
carer was most often partner or spouse (72%). Although there was no difference in carer SF-
12 physical component score at 3 months, there was less decline in carer SF-12 mental 
component score (difference -2·1, 95 CI -3·9--0·3, p=0·02; Table 3) although this was not 
maintained with longer follow-up (eTables 3 and 4). 
Adverse Events 
Targeted adverse events are detailed in eTable 5. There were no differences in adverse 
events between trial arms at 3 or 15 months.  
Discussion 
PD REHAB showed that physiotherapy and occupational therapy produced no clinically 
meaningful immediate or medium term beneficial effects on ADL or QOL in mild to moderate 
Parkinson’s disease. The medium term significant differences in QOL measured by PDQ-39 
summary index and EuroQol EQ-5D quotient in favour of therapy were small and did not 
reach clinically significant levels which we defined as twice MCIC levels. 
Our Cochrane review of physiotherapy versus no intervention in Parkinson's disease 
showed that all forms of physical therapy produced small benefits in motor function and ADL, 
but no change in QOL.19 The Cochrane review of occupational therapy found insufficient 
evidence about effectiveness in two small trials,4 although a recent large (n=191) Dutch trial 
found that occupational therapy improved self-perceived performance, but not QOL.20 The 
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absence of any motor effect (PDQ-39 mobility domain) or response in ADL in PD REHAB is 
likely to be multifactorial, due to early disease stage of most patients, low ‘dose’ of 
intervention, and lack of consistency in therapy assessment and intervention.  
Traditionally, physiotherapy and occupational therapy have been used in the more advanced 
stages of Parkinson’s disease, once imbalance and falls have developed (H&Y ≥3).1 As a 
result of using the uncertainty principle for recruitment, most patients in PD REHAB had H&Y 
less than three at randomisation. It is possible that such mild to moderate disease may not 
respond to the therapies, whereas more severe disease may respond, although this remains 
to be established. As a consequence, the results of PD REHAB can only be generalised to 
patients with mild to moderate disease. 
Median therapy ‘dose’ was four sessions of 58 minutes over 8 weeks for both therapies 
combined. This is low in comparison with the previous five physiotherapy trials in the 
Cochrane review (5 to 52 weeks therapy).3 A Dutch trial of physiotherapy in Parkinson’s 
disease (ParkNet)21 also showed no evidence in favour of therapy. Total contact time 
between patients and physiotherapists over 6 months in ParkNet was 15 sessions of 30 
minutes, nearly double that in PD REHAB.21 Importantly though, the dose delivered in PD 
REHAB reflects routine NHS practice. 
Therapy expert groups recommended an individual ‘goal setting’ approach for PD REHAB 
interventions, as this is the gold standard and addresses the personalised needs and wishes 
of the individual. Therapy content was in keeping with NHS and European guidelines on 
physiotherapy and occupational therapy.8-11 However, an individualised goal setting 
approach with this content may not be transferable to patients with mild disease. The lack of 
task-related practice is of particular concern as this has been shown to be a significant factor 
in stroke rehabilitation trials.2 We were also concerned by the low prescription and dose of 
exercise in PD REHAB. 
The possibility that patients with more severe disease might show a better response was 
examined in a planned subgroup analysis examining response according to baseline NEADL 
score and Hoehn and Yahr stage. Whilst the data did not support this hypothesis, the 
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numbers with severe disease were small, so this is likely to be under-powered. Similarly, 
older patients might respond better to the therapies because of greater levels of frailty and 
co-morbidities, but there was no evidence of this in the subgroup analysis. 
The fidelity of the intervention was reasonable in both arms of this pragmatic ‘real-world’ trial. 
In the therapies arm, 93% of patients received therapies within 3 months of randomisation. 
Whereas, only 2% of the no therapy arm crossed-over to receive treatment within 3 months, 
mainly due to motor progression. It is unlikely that these small proportions of cross-overs led 
to the lack of effect seen in the trial. 
In spite of all patients reporting ADL problems at baseline, many had mild disease. 29% had 
a NEADL score at baseline of >61 and 14% had a score of ≥65 (mean baseline score 
51/66). This may have led to a floor effect, since the NEADL score could not improve much 
from a good baseline score. However, planned subgroup analysis showed that there was still 
no response in patients with more severe baseline NEADL scores. It should also be noted 
that the NEADL results are supported by the lack of a clinically meaningful effect on PDQ-39 
ADL domain. 
Conclusions 
Physiotherapy and occupational therapy using an individual goal setting approach produced 
no clinically meaningful short or medium term benefits in ADL or QOL in patients with mild to 
moderate Parkinson's disease. This evidence does not support the use of low dose, goal-
directed physiotherapy and occupational therapy in patients in the early stages of 
Parkinson’s disease. Future research should explore the development and testing of more 
structured and intensive physical therapy programmes in patients with all stages of 
Parkinson’s disease. 
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Table 1 Demographics and baseline characteristics 
 
  PT/OT No therapy 
Number of patients randomised  381 381 
Demographics    
Age (years) Mean (SD) 70 (9.1) 70 (9.3) 
 Range 35 – 90  35 – 91  
    
Age category (years) <60 47 (12%) 46 (12%) 
 60-69 129 (34%) 129 (34%) 
 70-79 148 (39%) 151 (40%) 
 ≥80 57 (15%) 55 (14%) 
    
Gender Male (N, %) 240 (63%) 258 (68%) 
    
Body Mass Index (kg/m2) N 327 333 
 Mean (SD) 27.2 (5.4) 26.9 (4.4) 
 Range 16.5 – 54.9 16.8 – 44.0 
Stage of Parkinson’s disease    
Duration of PD (years) N 381 379 
 Mean (SD) 4.5 (4.9) 4.6 (4.5) 
 Median (IQR) 3.0 (1.0 – 6.1) 3.3 (1.3 – 6.4) 
 Range 0.01 – 29.9 0 – 25.6 
    
Hoehn & Yahr stage ≤2·0 254 (67%) 254 (67%) 
 2·5 46 (12%) 46 (12%) 
 3·0 61 (16%) 61 (16%) 
 ≥4·0 20 (5%) 20 (5%) 
Drug dose    
Levodopa equivalent dose (mg/day) N 381 381 
 Mean (SD) 453 (357.9) 498 (372.8) 
 Range 0 – 1877  0 – 2181 
NEADL scale    
Total score N 381 381 
 Mean (SD) 51 (12.9) 51 (13.3) 
 Median (IQR) 53 (43 – 61) 54 (42 – 62) 
 Range 6 – 66  8 – 66  
    
NEADL total score category 0-21 (severe) 14 (4%) 14 (4%) 
22-43 (moderate) 88 (23%) 88 (23%) 
 44-66 (mild) 279 (73%) 279 (73%) 
PDQ-39    
Summary index N 380 377 
 Mean (SD) 23.8 (14.5) 23.7 (14.4) 
 Median (IQR) 22.4 (12.6 – 32.3) 21.1 (12.2 – 33.0) 
 Range 2.4 – 78.4 1.9 – 67.4 
NEADL=Nottingham Extended Activities of Daily Living (total score ranges from 0 to 66, where higher scores are 
better); PDQ-39=Parkinson’s Disease Questionnaire-39 (summary index ranges from 0 to 100, where lower scores 
are better); SD=Standard Deviation; IQR=Interquartile Range. Age, Hoehn & Yahr stage and NEADL total score 
were minimisation variables in the randomisation algorithm. 
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Table 2 Patient activities of daily living and quality of life scores at 3 months 
 
 Baseline 3 months Mean change from baseline Mean difference 
(95% CI)† p-value  PT/OT No therapy PT/OT No therapy PT/OT No therapy 
NEADL 
Total score N=381 N=381 N=294 N=304 N=294 N=304 0.5 (-0.7 to 1.7) 0.4 50.5 (12.9) 50.9 (13.3) 49.6 (14.0) 50.3 (14.5) -1.5 (7.8) -1.0 (7.4) 
Mobility N=376 N=372 N=338 N=338 N=334 N=330 0.1 (-0.3 to 0.5) 0.6 13.9 (4.0) 13.8 (4.2) 13.6 (4.2) 13.6 (4.4) -0.4 (2.6) -0.2 (2.4) 
Kitchen Activities N=379 N=373 N=337 N=337 N=335 N=329 0.005 (-0.3 to 0.3) 1.0 13.0 (2.7) 13.0 (2.9) 13·0 (3.0) 12.9 (3.2) -0.2 (2.2) -0.2 (1.9) 
Domestic Tasks N=374 N=370 N=330 N=332 N=325 N=323 0.5 (-0.06 to 1.0) 0.08 10.9 (4.2) 11.1 (4.3) 10.4 (4.5) 10.8 (4.4) -0.8 (3.4) -0.3 (3.2) 
Leisure Activities N=376 N=365 N=318 N=329 N=316 N=318 0.01 (-0.4 to 0.4) 0.9 12.9 (4.1) 13.0 (4.0) 13.0 (4.1) 13.1 (4.0) -0.2 (2.4) -0.1 (2.4) 
PDQ-39 
 N=380 N=377 N=349 N=351 N=348 N=347   
Mobility 32.7 (26.1) 31.3 (25.8) 33.2 (27.3) 33.3 (28.0) 1.1 (17.1) 2.6 (15.8) -1.5 (-3.9 to 1.0) 0.2 
Activities of Daily Living 31.3 (23.1) 30.6 (21.8) 32.1 (23.8) 31.5 (23.8) 1.6 (14.3) 1.0 (16.7) 0.7 (-1.7 to 3.0) 0.6 
Emotional Well-being 23.9 (18.5) 23.0 (18.1) 25.9 (19.8) 25.5 (20.3) 2.6 (13.1) 3.0 (16.8) -0.5 (-2.7 to 1.8) 0.7 
Stigma 18.3 (22.9) 17.1 (21.0) 19.8 (23.1) 17.6 (21.3) 1.6 (17.7) 0.9 (17.5) 0.7 (-2.0 to 3.3) 0.6 
Social Support 6.6 (14.0) 5.7 (11.0) 10.3 (17.4) 9.3 (15.1) 3.6 (15.6) 3.8 (14.9) -0.2 (-2.5 to 2.0) 0.8 
Cognition 26.6 (20.1) 27.3 (21.1) 28.8 (20.6) 29.6 (21.6) 2.2 (16.5) 2.2 (17.0) -0.05 (-2.6 to 2.4) 1.0 
Communication 16.5 (18.2) 18.5 (19.8) 20.8 (20.1) 21.8 (21.1) 4.8 (15.7) 3.0 (17.4) 1.8 (-0.7 to 4.2) 0.2 
Bodily Discomfort 34.8 (23.4) 35.9 (24.0) 36.5 (24.4) 38.6 (24.1) 2.0 (20.7) 2.8 (21.1) -0.8 (-3.9 to 2.3) 0.6 
Summary Index 23.8 (14.5) 23.7 (14.4) 25.9 (16.5) 25.9 (16.5) 2.4 (9.5) 2.4 (10.8) 0.007 (-1.5 to 1.5) 1.0 
EQ-5D 
Quotient Score N=378 N=374 N=345 N=345 N=342 N=338 -0.03 (-0.07 to -
0.002) 0.04  0.64 (0.27) 0.66 (0.25) 0.65 (0.25) 0.63 (0.26) 0.002 (0.23) -0.03 (0.21) 
Visual Analogue Score N=376 N=376 N=346 N=347 N=341 N=342 -0.2 (-2.6 to 2.2) 0.9  68.5 (17.5) 68.6 (17.0) 67.4 (18.2) 66.8 (17.8) -1.8 (17.1) -1.9 (14.3) 
Data is mean (SD). NEADL total score: ranges from 0 to 66 where higher scores are better and a positive change is an improvement in score. PDQ-39: ranges from 0 to 100 where lower scores 
are better and a negative change is an improvement in score. EQ-5D quotient: ranges from -0·59 to 1 where higher scores are better and a positive change is an improvement in score. EQ-5D 
VAS: ranges from 0 to 100 where higher scores are better and a positive change is an improvement in score. 
† To aid interpretation, regardless of scale, a positive mean difference favours no therapy group and a negative mean difference favours PT/OT group. 
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Table 3 Carer quality of life scores 
 
 Baseline 3 months Mean change from baseline Mean difference 
(95% CI)† p-value  PT/OT No therapy PT/OT No therapy PT/OT No therapy 
SF-12 
Physical functioning N=171 N=181 N=169 N=181 N=151 N=156 -5.6 (-11.0 to -0.2) 0.04  70.3 (35.4) 76.0 (30.5) 68.6 (35.8) 70.3 (30.0) -0.7 (24.8) -6.3 (23.0) 
Role physical N=173 N=183 N=169 N=185 N=155 N=163 -0.5 (-5.3 to 4.3) 0.8  75.4 (28.5) 76.7 (26.8) 69.8 (28.8) 71.0 (27.1) -5.4 (19.6) -5.9 (23.8) 
Role emotional N=172 N=182 N=170 N=183 N=155 N=162 -4.4 (-9.0 to 0.2) 0.06  83.6 (23.1) 81.9 (22.9) 80.4 (24.2) 76.4 (24.9) -1.7 (20.0) -6.1 (21.5) 
Social functioning N=175 N=186 N=171 N=189 N=157 N=169 -3.8 (-8.9 to 1.3) 0.1  84.9 (22.9) 83.3 (23.6) 81.0 (24.5) 78.3 (26.9) -2.9 (21.9) -6.7 (24.5) 
Mental health N=174 N=183 N=170 N=188 N=156 N=167 -4.3 (-8.2 to -0.4) 0.03  68.8 (21.1) 68.6 (18.5) 67.6 (20.2) 64.6 (21.9) -0.2 (16.7) -4.5 (18.9) 
Vitality N=175 N=184 N=170 N=188 N=156 N=167 -4.6 (-9.2 to 0.05) 0.05  57.4 (25.6) 61.8 (22.6) 53.8 (25.9) 53.2 (24.5) -3.5 (21.0) -8.1 (21.1) 
Bodily pain N=173 N=184 N=170 N=189 N=156 N=168 2.9 (-2.2 to 7.9) 0.3  77.7 (29.3) 76.4 (28.7) 74.1 (28.8) 74.2 (28.5) -4.6 (25.0) -1.8 (21.1) 
General health N=174 N=186 N=170 N=190 N=155 N=170 -0.9 (-5.0 to 3.3) 0.7  64.2 (25.3) 65.6 (26.1) 58.9 (26.0) 61.0 (25.3) -4.4 (18.6) -5.3 (19.5) 
Physical component score N=166 N=171 N=165 N=174 N=146 N=144 -0.6 (-2.3 to 1.2) 0.5  47.1 (12.5) 48.2 (11.4) 45.1 (13.3) 46.4 (11.6) -1.6 (7.5) -2.1 (7.5) 
Mental component score N=166 N=171 N=165 N=174 N=146 N=144 -2.1 (-3.9 to -0.3) 0.02  51.1 (10.2) 50.1 (8.9) 49.7 (10.2) 48.0 (10.5) -0.5 (7.6) -2.6 (7.9) 
 
SF-12: ranges from 0 – 100 where higher scores are better and a positive change is an improvement in score. 
† To aid interpretation, regardless of scale, a positive mean difference favours no therapy group and a negative mean difference favours PT/OT group. 
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Figure legends 
 
 
Figure 1 CONSORT diagram for PD REHAB. Patient recruitment and follow-up 
 
Figure 2 Medium term scores in activities of daily living and quality of life 
 
eFigure 1 Subgroup analyses for NEADL total score at 3 months 
 
